Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

Velcade Performing Well In Confirmatory Phase III Trial

Dec. 16, 2003

Millennium Pharmaceuticals Inc. stopped dosing the control arm of a confirmatory Phase III trial of Velcade, a cancer drug, after an independent review committee uncovered positive data in a prespecified interim analysis. (BioWorld Today)

Velcade Performing Well In Confirmatory Phase III Trial

Dec. 16, 2003

Millennium Pharmaceuticals Inc. stopped dosing the control arm of a confirmatory Phase III trial of Velcade, a cancer drug, after an independent review committee uncovered positive data in a prespecified interim analysis. (BioWorld Today)

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Dec. 15, 2003

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld Today)

Acambis Files 'First-Ever' BLA: Arilvax Vaccine In Yellow Fever

Dec. 15, 2003

Acambis plc filed a biologics license application seeking approval of Arilvax as a vaccine to prevent yellow fever. (BioWorld Today)

FDA Rule: Electronic Labeling For Drug Product Submissions

Dec. 12, 2003

FDA Rule: Electronic Labeling For Drug Product Submissions

Dec. 12, 2003

Guilford Raising $27.4M; Plans For Aggrastat, Aquavan In Line

Dec. 11, 2003

GlycoFi's Third Round Brings In $10M For Expansion Plans

Dec. 11, 2003

Guilford Raising $27.4M; Plans For Aggrastat, Aquavan In Line

Dec. 11, 2003

GlycoFi's Third Round Brings In $10M For Expansion Plans

Dec. 11, 2003

View All Articles by Kim Coghill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...